Integration of Immunotherapy into Adjuvant Therapy for Resected Non-Small-Cell Lung Cancer: ALCHEMIST Chemo-Io (ACCIO)
Jacob Sands, Sumithra J. Mandrekar, David Kozono, Geoffrey R. Oxnard, Shauna L. Hillman, Dennis A. Wigle, Ramaswamy Govindan, Jennifer W. Carlisle, Jhanelle E. Gray, Joseph K. Salama, Luis E. Raez, Apar Kishor Ganti, Nathan R. Foster, Shakun Malik, Jeffrey D. Bradley, Karen Kelly, Suresh S. Ramalingam, Thomas E. Stinchcombe
Abstract
Non-small-cell lung cancer (NSCLC) causes significant mortality each year. After successful resection of disease stage IB (>4 cm) to IIIA (per AJCC 7), adjuvant platinum-based chemotherapy improves median overall survival and is the standard of care, but many patients still experience recurrence of disease. An adjuvant regimen with greater efficacy could substantially improve outcomes. Pembrolizumab, a programmed cell death-1 inhibitor, has become an important option in the treatment of metastatic NSCLC. ALCHEMIST is a clinical trial platform of the National Cancer Institute that includes biomarker analysis for resected NSCLC and supports therapeutic trials including A081801 (ACCIO), a three-arm study that will evaluate both concurrent chemotherapy plus pembrolizumab and sequential chemotherapy followed by pembrolizumab to standard of care adjuvant platinum-based chemotherapy. Clinical trial registration: NCT04267848 (ClinicalTrials.gov)